title: Does suprascapular nerve block reduce shoulder pain following stroke: a double-blind randomised controlled trial with masked outcome assessment.
abstract: BACKGROUND
  Shoulder pain is a common complication of a stroke which can impede participation in rehabilitation programs and has been associated with poorer outcomes. The evidence base for current medical and therapeutic management options of hemiplegic shoulder pain is limited. This study will evaluate the use of suprascapular nerve block injection as part of an interdisciplinary approach to the treatment of shoulder pain following stroke. The technique has previously been proven safe and effective in the treatment of shoulder pain associated with rheumatoid arthritis and degenerative shoulder conditions but its usefulness in a stroke population is unclear.
  
  
  METHODS
  A double blind randomised placebo controlled trial will assess the effect of a suprascapular nerve block compared with placebo in a population of 66 stroke patients. The trial will measure effect of injection on the primary outcome of pain, and secondary outcomes of function and quality of life. Measurements will take place at baseline, and 1, 4 and 12 weeks post intervention. Both groups will continue to receive routine physiotherapy and standard ward care.
  
  
  CONCLUSIONS
  The results of this study could reduce pain symptoms in persons with mechanical shoulder pain post stroke and provide improvement in upper limb function.
  
  
  BACKGROUND
  This trial is registered with the Australian New Zealand Clinical Trials Registry (ANZCTR) - ACTRN12609000621213.
authors.affiliation: Division of Rehabilitation, Aged Care and Allied Health, Repatriation General Hospital, Daw Park, South Australia, Australia. zoe.allen@health.sa.gov.au
authors.forename: Zoe A
authors.initials: ZA
authors.lastname: Allen
authors.forename: E Michael
authors.initials: EM
authors.lastname: Shanahan
authors.forename: Maria
authors.initials: M
authors.lastname: Crotty
mesh_terms: D000779:Anesthetics, Local / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D002045:Bupivacaine / Q000627:therapeutic use; D004185:Disability Evaluation; D004311:Double-Blind Method; D006801:Humans; D008775:Methylprednisolone / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077555:Methylprednisolone Acetate; D009407:Nerve Block; D009520:New Zealand; D010147:Pain Measurement; D011788:Quality of Life; D016059:Range of Motion, Articular; D012107:Research Design; D020069:Shoulder Pain / Q000209:etiology / Q000601:surgery*; D020521:Stroke / Q000150:complications*
chemical_list: D000779:Anesthetics, Local; D000893:Anti-Inflammatory Agents; D000077555:Methylprednisolone Acetate; D008775:Methylprednisolone; D002045:Bupivacaine